The Basics Of Neuroendocrine Pancreatic Tumors
Neuroendocrine pancreatic tumors are a kind of growth occurring in the pancreas. They develop in the islets of Langerhans, the endocrine cells in the pancreas. These cells' job is to produce hormones needed in digestion and blood sugar regulation. When these cells malfunction, symptoms such as diabetes, dermatitis, nausea, hunger, tremors, weight gain, episodic sweating, rapid heart rate, and even central nervous system problems can occur. Tumors that develop in these cells can either be functioning (they secrete hormones) or nonfunctioning. Most are functioning, malignant, and grow slowly.
Pancreatic neuroendocrine tumors are quite rare compared to other types of pancreas tumors. Reports state that two or three thousand cases are found each year in the United States. That's an incidence rate of around five people in every one million every year.
Of the types of pancreatic tumors, neuroendocrine tumors are preferable to the usual type, the adenocarcinoma. While the survival rate of adenocarcinoma sufferers is quite low, about 5 to 12 months after diagnosis, nonfunctional metastatic neuroendocrine tumors have better rates. They average rate is near 5 years, and only about sixty percent are malignant. Also, the abnormal chemicals and hormones the tumors secrete often warn of their presence early. The chemical profiles are also helpful in determining what type of tumor has developed on the pancreas. Doctors then use radiographic technology to find the tumor's location. Though techniques vary, the common imaging practices include radio-contrast dynamic CT scans, transabdominal ultrasound, octreotide scintigraphy, and selective visceral angiography. The techniques provide imaging information about the neoplasm and are used based on the individual person.
When the tumor is located and profiled, it is usually one of three types: insulinomas, gastrinomas, and glucagonoma. Insulinomas are rarely cancerous. They alert to their presence by the hormone they over-secrete: insulin. The hormone causes hypoglycemia, or low blood sugar. Eating relieves the problem. Symptoms such as tremors, weight gain, nausea, episodic sweating, hunger, and seizures also occur. Gastrinomas create large amounts of the hormone gastrin. Its over-secretion results in Zollinger-Ellison syndrome, which includes gastric hyperacidity (related to heartburn) and peptic ulcer formation. Glucagonomas secrete glucacon. They cause mild diabetes and often advanced dermatitis. The tumors are usually two inches or more in diameter at the time of diagnosis. Seventy percent of glucagonomas are cancerous. When cancerous neuroendocrine pancreatic tumors metastasize, they usually affect the liver. To treat this, doctors have tried blocking the hepatic artery. This is intended to starve the metastatic liver tumor of nutrients. Also, some studies use the principles of radioimmunotherapy. With this technique, the radioactive elements join with compound chosen for their specific properties. They target the tissue of islet cells. This is important, for treatments must be designed for tumor types if they are to be effective. Before they begin treatment, doctors compensate for the specific hormone that the tumor is over-secreting. For this they may use H2-blockers, octreotide, or omeprazole, depending on the neoplasm type. For non-metastasized tumor, surgery to remove the growth is the most common option. But if it has metastasized, chemotherapy is a more effective choice. Agents like dacarbazine, Gemzar, streptozocin, doxorubicin, and 5 -FU are common. Neuroendocrine pancreatic tumors, though not as dangerous as other types of pancreas cancer, can still be fatal if they are malignant. But, if doctors catch the tumor early, it may be possible to remove it via surgery before it metastasizes. Thus, one should be alert to the symptoms and take immediate action if a tumor is suspected.
|
